Caffeine Citrate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
CAFFEINE CITRATE: Drug Repurposing Evaluation — TxGNN Predictions Not Available
One-Sentence Summary
Caffeine Citrate is a xanthine derivative formulation, with no original indication data recorded in this evidence pack. The TxGNN model has not generated any predicted indications for this candidate — the evidence pack contains critical data gaps that prevent a complete repurposing evaluation. At present, no clinical trial or literature evidence can be linked to a repurposing target.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions generated |
| Norway Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Prediction is Available
The TxGNN pipeline returned an empty predicted_indications array for Caffeine Citrate. Three likely causes explain this outcome:
Missing graph identity. The DrugBank ID is not recorded in the evidence pack. Caffeine Citrate is a salt/citric acid co-formulation of caffeine (DrugBank: DB00201), and without a resolved node identity, the knowledge graph cannot correctly anchor this compound for link prediction.
Absent mechanism of action data. MOA data is marked as a high-severity data gap. Without pharmacological feature vectors, the TxGNN model cannot identify mechanistic similarity to disease nodes, which is central to its prediction logic.
Possible entity mismatch. The pipeline may have attempted to match "CAFFEINE CITRATE" as a distinct entity rather than mapping it to the parent caffeine node. A re-run with the correct DrugBank ID and entity mapping is needed before any prediction can be interpreted.
Norway Market Information
No authorizations are on record. Caffeine Citrate is not marketed in Norway under this name at the time of data collection (2026-04-20).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack produces no TxGNN predicted indications, records no original indications, and contains blocking-level safety data gaps — a repurposing evaluation cannot be meaningfully completed until the issues below are resolved.
To proceed, the following is needed:
- Resolve DrugBank ID: Confirm mapping to DB00201 (caffeine) or identify a distinct Caffeine Citrate entry; update the pipeline's drug node accordingly
- Re-run TxGNN pipeline: Execute with the corrected drug node to generate
predicted_indications - Retrieve MOA data: Query DrugBank API for mechanism of action (xanthine / adenosine receptor antagonism / phosphodiesterase inhibition)
- Retrieve safety data: Download and parse the package insert PDF from the relevant regulatory authority to populate warnings and contraindications
- Confirm original approved indication(s): Caffeine Citrate is clinically established for apnea of prematurity in neonates — this should be recorded as the reference indication before repurposing analysis proceeds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.